CytoDyn Inc. (OTCMKTS:CYDY) Files An 8-K Entry into a Material Definitive AgreementItem 1.01
Between November20, 2017 and November21, 2017, CytoDyn Inc., a Delaware corporation (the “Company”), issued in private placements to accredited investors an aggregate of 2,810,000 shares of its common stock, par value $0.001 per share, together with warrants to purchase an aggregate of 2,810,000 shares of common stock at an exercise price of $0.75 per share. The securities were issued at a combined purchase price of $0.50 per fixed combination of one share of common stock and one warrant to purchase one share of common stock, for aggregate gross proceeds to the Company of approximately $1.4 million. The warrants have a five-year term and are immediately exercisable. Copies of the forms of warrant and subscription agreement are incorporated herein by reference to Exhibits 4.1 and 10.1, respectively, to the Form 8-K filed on November8, 2017.
As a fee to the placement agent, the Company has agreed to pay a cash fee equal to 12% of the gross proceeds received from qualified investors in the offering, or $81,600 for the closings to which this Form8-K relates, as well as a one-time non-accountable expense fee of $25,000 in the aggregate for all closings. The Company also agreed to grant the placement agent or its designees warrants to purchase up to 10% of the number of shares of common stock sold to qualified investors in the offering, or 136,000 shares for the closings to which this Form8-K relates, on terms similar to the investor warrants described above.
The Company relied on the exemption provided by Rule 506 of Regulation D and Section4(a)(2) of the Securities Act of 1933, as amended, in connection with the foregoing transactions.
After giving effect to the foregoing transactions, the number of shares of common stock outstanding as of November21, 2017 was 163,190,139. As of November21, 2017, there were outstanding warrants to purchase 75,680,114 shares of common stock (including warrants issued to investors in this offering), with an average weighted exercise price of $0.83 per share.
| Item 1.01 | Unregistered Sales of Equity Securities. |
The disclosure in Item 1.01 of this Form 8-K is incorporated by reference into this Item 1.01.
| Item 1.01 | Financial Statements and Exhibits. |
(d) Exhibits.
1
About CytoDyn Inc. (OTCMKTS:CYDY)
CytoDyn Inc. is a clinical-stage biotechnology company. The Company is focused on the clinical development and commercialization of humanized monoclonal antibodies to treat Human Immunodeficiency Virus (HIV) infection. The Company’s lead product candidate, PRO 140, belongs to a class of HIV therapies known as entry inhibitors that block HIV from entering into and infecting certain cells. The Company’s product pipeline also includes Cytolin and CytoFeline. Cytolin is a mouse monoclonal antibody developed to identify a specific type of immune cell called a cytotoxic T cell, or cytotoxic T lymphocyte (CTL). CytoFeline is an anti-lymphocyte function-associated antigen-1 (LFA-1) antibody for the treatment of Feline Immunodeficiency Virus (FIV) infection. PRO 140 blocks HIV from entering a cell by binding to a molecule called C-C chemokine receptor type 5 (CCR5). The Company has finished Phase II clinical trials for PRO 140 with demonstrated antiviral activity in man.